Lagan, Jakub http://orcid.org/0000-0003-0017-9082
Naish, Josephine H.
Bradley, Joshua
Fortune, Christien
Palmer, Charlie
Clark, David
Schelbert, Erik B.
Schmitt, Matthias
Bright-Thomas, Rowland
Miller, Christopher A.
Funding for this research was provided by:
british heart foundation (FS/17/47/32805, AA/18/4/34221)
national institute for health research (CS-2015-15-003)
Article History
Received: 29 July 2021
Accepted: 11 December 2021
First Online: 7 January 2022
Declarations
:
: J.L. reports a grant from British Heart Foundation (Clinical Research Training Fellowship). C.A.M. reports grants from National Institute for Health Research, UK and from British Heart Foundation during the conduct of the study and research support from Amicus Therapeutics, Guerbet Laboratories Limited, Roche and Univar Solutions B.V. outside of the submitted work. C.A.M. has served on an advisory board for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca, and serves as an advisor for HAYA therapeutics and PureTech Health. J.H.N., J.B., C.F., C.P., D.C., E.B.S., M.S. and R.B.T. have nothing to disclose. The sponsor and funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
: The Research Ethics Committee North West—Greater Manchester South approved the study (reference number 14/NW/1088). Written informed consent was obtained from all participants. The work was conducted according to the Helsinki Declaration.
: Not applicable.